The Journal of Immunology, Vol 134, Issue 5 3291-3297, Copyright © 1985 by American Association of Immunologists

ARTICLES

Clearance of IgE from serum of normal and hybridoma-bearing mice

S Haba, Z Ovary and A Nisonoff

The half-life of IgE in the mouse was investigated by using radiolabeled and unlabeled monoclonal antibodies of the IgE class. Quantitative serologic assays were used for the unlabeled antibodies. IgE was cleared rapidly upon i.v. inoculation; after 48 hr, less than 0.2% of the initial concentration remained in the serum. The IgE was cleared initially with a half-life of 1 to 2 hr, attaining a relatively constant value of 5 to 8 hr. The corresponding values for IgG1, determined as a control, were 11 to 12 hr and 9 to 11 days, respectively. The initial stage probably reflects equilibration with extravascular spaces. This is supported by experiments with mice in which IgE-secreting tumors were implanted and then resected; IgE was cleared from such mice with an average initial half-life of about 5 hr. The rates of clearance of inoculated IgE were approximately the same in mice bearing an IgE-secreting tumor and in normal mice. This suggests that the initial rapid clearance of IgE from normal mice is not due to adherence of IgE to saturable sites; such sites might be expected to be occupied in mice expressing high serum concentrations of IgE. This conclusion was supported by experiments in which 1-mg quantities of IgE were inoculated i.v. into normal mice daily for 6 days. Additional IgE injected on day 7 was cleared normally. The results obtained with tumor- bearing mice indicate that the reported failure to elicit an IgE response to an antigen in mice bearing IgE-secreting hybridomas cannot be attributed to rapid clearance of newly synthesized IgE in such mice, as compared with normal mice.

This article has been cited by other articles:

				S. C. Fish, D. D. Donaldson, S. J. Goldman, C. M. M. Williams, and M. T. Kasaian IgE Generation and Mast Cell Effector Function in Mice Deficient in IL-4 and IL-13 J. Immunol., June 15, 2005; 174(12): 7716 - 7724. [Abstract] [Full Text] [PDF]

				M. A. C. de Lafaille, S. Muriglan, M.-J. Sunshine, Y. Lei, N. Kutchukhidze, G. C. Furtado, A. K. Wensky, D. Olivares-Villagomez, and J. J. Lafaille Hyper Immunoglobulin E Response in Mice with Monoclonal Populations of B and T Lymphocytes"" J. Exp. Med., November 5, 2001; 194(9): 1349 - 1360. [Abstract] [Full Text] [PDF]

				M. E. Payet, E. C. Woodward, and D. H. Conrad Humoral Response Suppression Observed with CD23 Transgenics J. Immunol., July 1, 1999; 163(1): 217 - 223. [Abstract] [Full Text] [PDF]

				K. Matsuoka, C. Taya, S. Kubo, N. Toyama-Sorimachi, F. Kitamura, C. Ra, H. Yonekawa, and H. Karasuyama Establishment of antigen-specific IgE transgenic mice to study pathological and immunobiological roles of IgE in vivo Int. Immunol., June 1, 1999; 11(6): 987 - 994. [Abstract] [Full Text] [PDF]

				C. Lange, T. Schuler, and T. Blankenstein Interleukin 4 Gene-defective Mice Reconstituted with Wild-type Bone Marrow Fail to Produce Normal Immunoglobulin E Levels J. Exp. Med., May 4, 1998; 187(9): 1487 - 1493. [Abstract] [Full Text] [PDF]

				F Mitjans, D Sander, J Adan, A Sutter, J. Martinez, C. Jaggle, J. Moyano, H. Kreysch, J Piulats, and S. Goodman An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice J. Cell Sci., January 8, 1995; 108(8): 2825 - 2838. [Abstract] [PDF]